To date none of the directors have sold any shares so I guess...

To date none of the directors have sold any shares so I guess that is the only guide we have to go on sat this point in time. If you consider the size of the global market for the ePAT App then it is much bigger than ResAPP and ResAPP is now worth over $200M. As ePAT gets closer to approval to sell their App in the US, EU and Aust we should see serious value coming into ePAT. The advantage of being a fast follower behind ResAPP is that the approval process in the US will the shorter as ResAPP will have already paved the way for getting approval for a medical APP on a smart phone device. The thing management can do is get the deal over the line and then we can measure the new management team against the timeline they outlined in the last announcement to the ASX. At least they have been bold enough to outline a timeline which us shareholders can now hold them accountable to and we know when the first sales should occur by. Again, I point out that ResAPP has not yet got approval in the US to sell their APP and yet they are worth over $200M!